SAN DIEGO, Feb. 21, 2017 /PRNewswire/ -- ViaCyte, Inc.,
a privately-held regenerative medicine company, today announced
four presentations at upcoming healthcare events. ViaCyte is
advancing two novel cell replacement therapies as long-term
diabetes treatments. ViaCyte's product candidates have the
potential to provide a functional cure for patients with type 1
diabetes as well as an important therapy for patients with type 2
diabetes that depend on insulin to help control their disease.
Details of the presentations are as follows:
|
Event:
|
American Society
of Transplantation – Cutting Edge of Transplantation Pipeline
Session
|
|
Speaker:
|
Dr. Kevin D'Amour,
Vice President, Research and Chief Scientific Officer
|
|
Date/Time:
|
February 23, 10:00 AM
MST
|
|
Location:
|
Arizona Biltmore,
Phoenix
|
|
|
|
Event:
|
Keystone
Engineered Cells and Tissues as Platforms for Discovery and
Therapy
|
|
Speaker:
|
Dr. Kevin D'Amour,
Vice President, Research and Chief Scientific Officer
|
|
Date/Time:
|
March 9, 8:30 AM
EST
|
|
Location:
|
Fairmont Copley
Plaza, Boston
|
|
|
|
Event:
|
Center for Cell
& Gene Therapy Series at Baylor College of
Medicine
|
|
Speaker:
|
Dr. Kevin D'Amour,
Vice President, Research and Chief Scientific Officer
|
|
Date/Time:
|
April 4, 9:00 AM
EST
|
|
Location:
|
Baylor College of
Medicine, Houston
|
|
|
|
Event:
|
GTCbio 14th Stem
Cell Research & Regenerative Medicine Summit
|
|
Speaker:
|
Dr. Mark Zimmerman,
Vice President, Strategy and Business Development
|
|
Date/Time:
|
April 6, 8:30 AM
EST
|
|
Location:
|
Hyatt Regency,
Boston
|
For more information about ViaCyte's participation in industry
events, please visit:
http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company
developing novel cell replacement therapies as potential long-term
diabetes treatments to reduce the risk of hypoglycemia and
diabetes-related complications. ViaCyte's product candidates
are based on the derivation of pancreatic progenitor cells, which
are then implanted in a durable and retrievable encapsulation
device. Once implanted and matured, these cells are designed
to secrete insulin and other regulatory factors in response to
blood glucose levels. ViaCyte has two products in
development. The PEC-Direct product candidate delivers the
pancreatic progenitor cells in a non-immunoprotective device and is
being developed for type 1 diabetes patients that have severe
hypoglycemic episodes, extreme glycemic lability, and/or impaired
hypoglycemia awareness. The PEC-Encap (also known as VC-01)
product candidate delivers pancreatic progenitor cells in an
immunoprotective device designed to be administered without the
need for chronic immunosuppression thus expanding the potential
treatment to all patients that use insulin to control their
disease. ViaCyte is headquartered in San Diego, California with additional
operations in Athens,
Georgia. The Company is funded in part by the California
Institute for Regenerative Medicine (CIRM) and JDRF.
For more information on ViaCyte, please visit www.viacyte.com
and connect with ViaCyte here: www.twitter.com/viacyte and
www.facebook.com/viacyte.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viacyte-to-present-at-four-upcoming-healthcare-events-300409918.html
SOURCE ViaCyte, Inc.